«This is expected to be the first of many new innovative therapies made possible by the Wyss Institute's collaborative model of translational research that will
enter human clinical trials,» said Wyss Founding Director Don Ingber, M.D., Ph.D., who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children's Hospital, and a Professor of Bioengineering at Harvard SEAS.